구동회

진료분야

위암/대장암/췌장암/담도암/GIST (항암화학요법/임상연구)

진료일정

  • 외래진료
  • 국내 학회
  • 국외 학회
  • 강의
  • 휴가
  • 기타
구분 월 화 수 목 금 토
오전
오후
온라인 진료예약 바로가기

학력 및 경력

[학력]
2002 경희대학교 의과대학 학사   
2007 울산대학교 의과대학 석사   
2014 울산대학교 의과대학 박사 

[경력]
2007 서울아산병원 인턴/내과 전공의
2010 국제진료의사 (KOICA) 캄보디아 캄퐁참 주립병원
2011 서울아산병원 종양내과 임상강사
2012-2023 현재 성균관의대 강북삼성병원 혈액종양내과 조교수/부교수
2017-2021 강북삼성병원 기획실 부실장
2019- 강북삼성병원 혈액종양내과 과장
2022- 강북삼성병원 임상시험센터 센터장
2023- 성균관의대 강북삼성병원 혈액종양내과 교수

학회 활동

[학회활동]
미국암학회(ASCO) 
대한내과학회(KAIM), 건강보험정책단 위원 
대한암학회(KCA), 홍보위원회 부위원장/ 재무위원회
대한위장관기질종양연구회(KGSG), 총무이사 
대한항암요법연구회(KCSG), 부총무
대한종양내과학회(KSMO), 보험정책위원회 간사/ 총무위원회 
대한위암학회(KGCA), 기획위원/학술위원 
식품의약품안전처(MFDS), 중앙약사심의위원
중앙임상시험심사위원회 (Central IRB), 위원
대한암완화？지지의료연구회 (KASCC) 홍보위원장
대한항암요법연구회 (KCSG), 위암/대장암/간췌담도 분과위원

[수상경력]
2011 한국암학술재단 장학생
2011 미국 샌안토니오 유방암 컨퍼런스 젊은 연구자상 
2012 한국암학술재단 보령학술상
2014 강북삼성병원 의학연구기금 신진과제
2015 삼성생명과학연구소(SBRI) 창의연구-공모과제
2018 일본종양내과학회 Travel Grant Award
2019 강북삼성병원 핵심가치실천상 (최상의료 부문)
2020 한국국제위암학회 최우수 포스터 발표상
2022 일본종양내과학회 Travel Grant Award 
2022 대한종양내과학회 국제심포지엄 최우수 포스터 발표상
2022 송천의학연구비 수여

대표 논문

[교신저자 혹은 제1저자 논문]
1. Kwon MY, Lee MY, Han YJ, Lee SH, Kim EJ, Park S, Lee YG, Koo DH*. Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients. PLoS One. 2023 Jan 6;18(1):e0280212. (*Corresponding author)

2. Koo DH, Han K, Park CY. Impact of cumulative hyperglycemic burden on the pancreatic cancer risk: A nationwide cohort study. Diabetes Res Clin Pract. 2023 Jan;195:110208.

3. Hong HP, Kim HO, Koo DH*, Lee YG, Kim MS, Ham SY, Kang DY, Oh TY, Lee H, Jung KU, Kim H. Clinical outcomes and prognostic factors of cone-beam CT-guided radiofrequency ablation for pulmonary metastases in colorectal cancer patients. Asia-Pac J Clin Oncol. 12 July 2022 [E-pub] (*Corresponding author)

4. Kim NH, Park JH, Koo DH*, Jung YS, Yang JY, Lee HY. A Pilot Study of Peritumor Administration of 5-FU for Preventing Bleeding in Advanced Gastric Cancer. Korean J Gastroenterol. 2022 Dec 25;80(6):273-280. (*Corresponding author)

5. Koo DH, Ryu MH, Lee MY, Moon MS, Kang YK. New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. World J Gastroenterol. 2021 Dec 28; 27(48): 8357-8369.

6. Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer Over a 16-year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. Cancer Res Treat. 2021 Apr;53(2):436-444.

7. Do IG, Jung KU, Koo DH*, Lee YG, Oh S, Kim K, Kim DH, Sohn JH, Son BH, Lee SR, Shin JH, Kim HO, Kim H, Chun HK, Serrero G, Yoo CH. Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progranulin expression. PLoS One. 2021 Jan 7;16(1):e0245153. (*Corresponding author)

8. Koo DH, Han KD, Kim HJ, Park CY. Middle-Aged Men with Type 2 Diabetes as Potential Candidates for Pancreatic Cancer Screening: A 10-Year Nationwide Population-Based Cohort Study. Acta Diabetol. 2020 Feb; 57 (2), 197-202.

9. Koo DH, Do IG, Oh S, Lee YG, Kim K, Sohn JH, et al. Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. Pathol Oncol Res. 2020 Jan;26(1):397-404.

10. Koo DH, Han KD, Park CY. The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study. J Clin Endocrinol Metab. 2019 Oct; 104 (10), 4594-4599.

11. Kwon MY, Cho HN, Koo DH*, Lee YG, Oh S, Lee SS. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. Korean J Intern Med. 2018 May;33(3):577-584. (*Corresponding author)

12. Go SI, Koo DH*, Kim ST, Song HN, Kim RB, Jang JS, Oh SY, et al. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist. 2017 Nov;22(11):1354-1361. (*Co-first author)

13. Kim JH, Do IG, Kim K, Sohn JH, Kim HJ, Jeon WK, Lee SR, Son BH, Shin JH, Nam H, Kwon HJ, Kim MS, Hong HP, Serrero G, Koo DH*; KBSMC Pancreatobiliary Cancer Team. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma. Cancer Chemother Pharmacol. 2016 Nov;78(5):1085-1092. (*Corresponding author)

14. Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, et al. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Res Treat. 2016 Oct;48(4):1155-1166.

15. Koo DH, Park I, Ahn JH, Lee DH, et al. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2016 Feb;77(2):339-47.

16. Kae YA, Lee MY, Park JS, Kim HJ, Jung TY, Jang BY, Kim YJ, Koo DH*. Ethical Attitudes according to Education and Clinical Experience of Do-Not-Resuscitate (DNR). Korean J Hosp Palliat Care. 2015 Sep;18(3):208-218. (*Corresponding author)

17. Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, et al. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol. 2015 Aug;36(8):5865-71.

18. Koo DH, Ryu MH, Ryoo BY, Seo J, Lee MY, et al. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12-years of experience at a single institution. Gastric Cancer. Gastric Cancer. 2015 Apr;18(2):346-53.

19. Koo DH, Kim K, Choi CM, Lee DH, Lee JC et al. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Cancer Chemother Pharmacol. 2015 Jan;75(1):197-206.

20. Koo DH, Ryu MH, Ryoo BY, Beck MY et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2015 Jan;75(1):173-82

21. Oh S, Koo DH*, Kwon MJ, Kim K, Suh C, et al. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Ann Hematol. 2014 Aug;93(8):1353-61. (*Co-first author)

22. Shin DS, Koo DH*, Yoo S, et al: Burnt-out Metastatic Prostate Cancer. Yeungnam Univ J Med. 2013 Dec;30(2):116-119. (*Corresponding author)

23. Koo DH, Oh S, Kim HJ, Jung HL. Long-term Follow-up of Hb Madrid Patient. Clin Pediatr Hematol Oncol. 2013 Apr;20(1):55-58.

24. Jeong EH, Koo DH*, Lee SH, et al. Aggressive Classical Kaposi’s Sarcoma Mimicking Malignant Lymphoma. Pathol Oncol Res. 2012 Oct;18(4):1067-9. (*Corresponding author)

25. Koo DH, Park CY, Lee ES, Ro J, Oh SW. Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study. PLoS One. 2012;7(6):e39880.

26. Koo DH, Ryu MH, Ryoo BY, Lee SS, Moon JH, et al. Three week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. Gastric Cancer. 2012 Jul;15(3):305-12.

27. Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63.

28. Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, et al. Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery. Oncology. 2011;80(3-4):208-13.

29. Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A Prognostic Model in Patients who Receive Chemotherapy for Metastatic or Recurrent Gastric Cancer: Validation and Comparison with Previous Models. Cancer Chemother Pharmacol. 2011 Oct;68(4):913-21.

30. Koo DH, Yun SC, Hong Y, Ryu M-H, Lee JL, Chang HM, et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer. 2011 May 27;11:205.

31. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, et al. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. Eur J Surg Oncol. 2007 Sep;33(7):843-8.

32. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, et al. A Phase II Study of Cetuximab (Erbitux) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. J Korean Med Sci. 2007 Sep;22 Suppl:S98-S103.

33. Koo DH, Lee SW, Song SY, Kim SY, Nam SY, Choi SH, et al. Comparison between Surgical and Non-Surgical Treatment of Squamous Cell Carcinoma of Tonsil：Retrospective Analysis of 87 Patients. Korean J Head Neck Oncol. 2007;23(1):p.3-8.

34. Koo DH, Oh JS, Choi S-H, Park HG, Lee SS, Kim MK, et al. Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. Korean J Hematol 2007 Sep; 42(3): 276 - 82.

35. Koo DH, Chang HM, Jung JY, Song JH, Lee JL, Ryu MH, et al. Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer. Clin Exp Dermatol. 2007 May;32(3):284-6.

36. Koo DH, Ko OB, Kim S, Lee DH, Kim SW, Suh C. Prospective Randomized Comparative Observations of Infectious Complications with or without Antimicrobial Prophylaxis, during Autologous Stem Cell Transplantation. Korean J Hematol 2006 Dec; 41(4): 282 - 8.

기타

닥터스토리
  • 정보보호관리체계(ISMS) 인증
  • 국제정보보호(ISO27001) 인증
  • 보건복지부
    의료기관 인증병원
  • 생명의학연구윤리 국제인증 획득
  • 美, 하원 표창장
  • 美, 존스홉킨스
    연구협약 체결